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ABSTRACT  
Objective: To examine the long-term relationship between sleep duration and type 2 diabetes or 
impaired glucose tolerance (IGT).   
Methods: Body composition measurements and self-reported sleep duration were determined in 
a longitudinal sample of 276 individuals aged 21 to 64 years followed for a mean of 6 years. Risk 
factors of type 2 diabetes/IGT over the follow-up were determined and relative risks (RRs) 
calculated for the development of type 2 diabetes/IGT by sleep duration group.  
Results: Independent risk factors of type 2 diabetes/IGT over the follow-up included age, 
obesity, sleep duration, and glucose/insulin homeostasis indicators. Using adults with 7-8 h of 
sleep as a reference, the adjusted RR for the development of type 2 diabetes/IGT was 2.78 (1.61-
4.12) for those with ≤6 h of sleep and 2.54 (1.42-3.53) for those with ≥9 h of sleep. These 
elevated RRs remained significant after adjustment for body mass index, waist circumference or 
percent body fat.  
Conclusion: Short and long sleeping times are associated with a higher risk of developing type 2 
diabetes/IGT, independent of several covariates. These results suggest that sleep duration may 
represent a novel risk factor for type 2 diabetes/IGT.   
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INTRODUCTION 
By 2010, diabetes is predicted to affect 221 million people globally, which would 
represent an increase of 46% from the year 2000 [1]. The continued rise in type 2 diabetes 
ensures that this metabolic disorder will remain of public health significance for decades to come. 
Patients with this condition require frequent contact with the health care system for effective 
management and prevention of complications, are at increased risk of hospitalization for 
conditions such as cardiovascular and kidney disease, and have 10 year reduction in life 
expectancy. Although lifestyle changes such as improving diet composition, increasing physical 
activity, and losing weight are the cornerstones of diabetes prevention, efforts are needed to 
better understand other determinants of the disease and to develop additional prevention 
strategies. Understanding the link between diabetes and sleep may represent an important part of 
that effort. 
Chronic partial sleep deprivation as a consequence of voluntary bedtime restriction is an 
endemic condition in modern society. In 1960, the American Cancer Society conducted a survey 
study in adults that showed modal sleep duration to be 8.0 to 8.9 h [2]. In 1995, a survey 
conducted by the National Sleep Foundation revealed that the mean sleep time had dropped to 7 h 
[3]. In 2004, more than 30% of adult men and women between the ages of 30 and 64 years 
reported sleeping less than 6 h per night [4]. Factors responsible for this situation include 
increases in environmental light, longer work days/longer commuting time, an increase in 
evening and night work, an increase in television use, and the advent of the personal computer 
and the Internet [5].  
A rapidly growing body of laboratory [6-8] and epidemiological [9-11] evidence suggests 
that chronic partial sleep deprivation, a behavior that is specific to the human species and appears 
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to have become more prevalent during the past few decades, may increase the risk of type 2 
diabetes. However, the underlying mechanisms of this presumed adverse influence of sleep 
deprivation on glucose metabolism is not well understood. Some data suggest that short-term 
partial sleep restriction could leads to insulin resistance by increasing sympathetic tone [12,13], 
raising evening cortisol concentrations [14], and decreasing cerebral glucose utilization [7,8]. 
These findings suggest that long-term sleep deprivation may predispose individuals to overt 
clinical diabetes. In a recent cross-sectional study, we have shown that short-duration sleepers 
had significantly lower glucose concentrations towards the end of an oral glucose challenge 
compared to average- and long-duration sleepers [15]. According to the glucostatic theory of 
appetite control [16], this represents a stimulus that can trigger episodes of hunger and 
spontaneous food intake, which may explain at least in part the greater risk of overweight 
displayed by short-duration sleepers, as shown in previous studies. 
The present study examines longitudinal associations between sleep duration and type 2 
diabetes or impaired glucose tolerance (IGT) in the Quebec Family Study (QFS). Furthermore, 
this study aims at examining glucose homeostasis in relation to sleep time, as an increase in 
energy intake and weight gain might be an unfortunate solution to restore glucose homeostasis in 
a context where insufficient sleep time becomes ingrained in the lifestyle of an individual. In this 
regard, we hypothesize that short sleep duration mediates its effects on diabetes through obesity.     
 
METHODS 
Subjects 
The QFS was initiated at Laval University in 1978. The primary objective of this study 
was to investigate the role of genetics in the etiology of obesity, fitness, and cardiovascular and 
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diabetes risk factors. In phase 1 of the study (1978 to 1981), a total of 1650 individuals from 375 
families were recruited and measured. Recruitment was conducted irrespective of body weight 
during phase 1, which resulted in a cohort with a wide range of body mass index (BMI; in 
kg/m2), 13.8-64.9. In phases 2 (1989-1994) and 3 (1995 to 2001), 100 families from phase 1 were 
re-tested, and an additional 123 families with at least one parent and one offspring with a BMI of 
≥32 were added to the cohort. Families were recruited through the media and were all French 
Canadians from the greater Quebec City area. This probability sample of the noninstitutionalized 
population of the greater Quebec City area comprised participants between the ages of 10 and 73 
years. Because no oral glucose tolerance tests (OGTT) were performed in phase 1, the present 
analyses are from participants involved in phases 2 and 3. From the sample of 223 Caucasian 
nuclear families, 163 men and 199 women were potentially eligible for longitudinal analyses 
between phases 2 and 3. Additional details about the QFS have been previously published [17]. 
In the current study, baseline corresponded to phase 2 and the mean duration of follow-up 
between phases 2 and 3 was 6.0 ± 0.9 years. The following exclusion criteria were applied: 1) age 
less than 21 years or greater than 64 years (27 men and 26 women excluded); 2) prevalent 
diabetes, defined as use of insulin or a hypoglycemic agent, a fasting plasma glucose level of 126 
mg/dL or more (≥7.0 mmol/L), or a 2 h postload plasma glucose level of 200 mg/dL or more 
(≥11.1 mmol/L) or glucose intolerant, defined as a 2 h postload plasma glucose level of 140 
mg/dL or more (≥7.8 mmol/L) (8 men and 3 women excluded); and 3) body weight change 
greater than 2 kg during the 6 months prior to baseline testing (5 men and 7 women excluded). 
The age range of this study was chosen to fit a definition of adults being between the ages of 21 
and 64, thus allowing a better generalization of the results obtained to this population. It is 
however relevant to mention that the results are not different with the inclusion of subjects under 
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21 and above 64 years of age. In addition, subjects with missing data on one or more of the 
variables investigated in one of the two testing sessions (baseline and 6 years later) were 
excluded (6 men and 4 women). The final longitudinal sample with full data included 276 
individuals (117 men and 159 women). All subjects provided written informed consent to 
participate in the study. The project was approved by the Medical Ethics Committee of Laval 
University.   
 
Sleep duration assessment 
The number of hours of sleep was assessed at baseline and year 6 through a question 
inserted in a self-administered questionnaire on physical activity participation. The question 
formulation was: “On average, how many hours do you sleep a day?” We then classified the 
subjects into 3 sleep duration groups: short-duration sleepers (≤6 hours of sleep; 21 men and 22 
women), average-duration sleepers (7-8 hours of sleep; 85 men and 112 women) and long-
duration sleepers (≥9 hours of sleep; 11 men and 25 women). We decided to classify the subjects 
into 3 sleep duration groups in order to have sufficient sample size in each category and the 
choice of the 7-8 hours of sleep per night as the reference category eased interpretation of the 
relative risks (RRs) since subjects who reported getting 7-8 hours of sleep had the lowest 
incidence of diabetes. Furthermore, this is the largest group and 7.6 and 8 hours are the mean and 
median numbers of hours of sleep per night in this cohort, respectively. Since there was no 
gender interaction with the other factors, data for both sexes were combined.   
 
Anthropometric and body composition measurements 
Height was measured to the nearest 0.1 cm using a standard stadiometer, and body weight 
was measured to the nearest 0.1 kg using a digital panel indicator scale (Beckman Industrial Ltd, 
 6
Model 610/612, Scotland, UK). Body mass index (BMI) was calculated as body weight divided 
by height squared (kg/m2). Waist circumference was measured at the line between the lower 
border of the last rib and the upper border of the iliac crest. These anthropometric measurements 
were performed according to standardized procedures recommended at the Airlie Conference 
[18]. Furthermore, body density was obtained from the mean of six valid measurements derived 
from underwater weighing [19]. Before immersion in the hydrostatic tank, the helium dilution 
method of Meneely and Kaltreider [20] was used to determine the pulmonary residual volume. 
The percentage of total body fat was determined from body density with the equation of Siri [21]. 
Body fat mass was estimated from body weight and the percentage of body fat. These 
measurements were performed in the same way at both baseline and after 6 years.    
 
Oral glucose tolerance test (OGTT) 
A 75 g OGTT was performed in the morning after a 12 h overnight fast. Blood samples 
were collected in tubes containing EDTA and Trasylol (Miles Pharmaceutics, Rexdale, ON, 
Canada) through a venous catheter from an antecubital vein at –15, 0, 15, 30, 45, 60, 90, 120, 150 
and 180 min. Plasma glucose concentration was measured enzymatically [22], whereas plasma 
insulin concentration was determined by radioimmunoassay with polyethylene glycol separation 
[23]. Fasting insulin and glucose concentrations were calculated as the mean of the –15 and 0 min 
concentrations. The total glucose or insulin area under the curve (AUC) and the glucose area 
below fasting glucose concentration (GABF) were calculated by the trapezoid method. We also 
calculated the homeostasis model assessment of insulin resistance (HOMA-IR) index [24].   
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Assessment of the risk of type 2 diabetes/IGT  
Type 2 diabetes and IGT were defined in accordance with the American Diabetes 
Association and the World Health Organization criteria [25,26]. We defined type 2 diabetes as 
use of insulin or a hypoglycemic agent, a fasting plasma glucose level of 126 mg/dL or more 
(≥7.0 mmol/L), or a 2 h postload plasma glucose level of 200 mg/dL or more (≥11.1 mmol/L). 
On the other hand, IGT was defined as a 2 h postload plasma glucose level of 140 mg/dL or more 
(≥7.8 mmol/L) in participants not meeting the criteria for type 2 diabetes.  
 
Potential covariates 
A broad set of potential covariates were measured via self-reported questionnaires at 
baseline and year 6. These include age, gender, study phase, length of follow-up, smoking habits 
[non or ex-smoker, light smoker (≤10 cigarettes per day), heavy smoker (>10 cigarettes per day)], 
employment status (student, paid employment, looking for work, home duties, retired, disabled), 
educational level (high school, pre-university level [CEGEP for Quebec], university), annual 
household income (categorized into five groups ranging from <$10,000 to $70,000 or more), 
menopausal status (pre-menopausal, post-menopausal), shift-working history (none, <5 years, ≥5 
years), resting metabolic rate (kcal/24 h using a ventilated hood and indirect calorimetry), 
physical activity level (min/day using a 3-day record), energy intake (kcal/day using a 3-day 
record), alcohol intake (g/day), and coffee intake (number of cups per day).      
 
Statistical analysis 
An unpaired Student’s t test was used to compare baseline characteristics between men 
and women. Baseline covariates and glucose homeostasis indicators were compared between the 
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three sleep duration groups using an analysis of variance (continuous variables) and chi-squared 
test for comparison of frequencies (categorical variables). A Tukey’s HSD post hoc test was 
performed to contrast mean differences between the sleep duration groups (continuous variables). 
Regression models were used to determine the association of these variables with the 
development of type 2 diabetes/IGT over the follow-up. In addition, multivariate logistic 
regression modeling was used to evaluate the relative risk for the development of type 2 
diabetes/IGT by sleep duration group. We also controlled for BMI, % body fat and waist 
circumference (one at a time) in order to determine if the adjustment for any of these adiposity 
indices attenuated the association of sleep time with type 2 diabetes/IGT. The power calculation 
analysis revealed that 40 subjects in each sleep duration group are sufficient to detect a RR of 2.0 
with an alpha of 0.05 and a power (1-β) of 80%. The power calculation is based on the 
assumption that there is an increase in the risk of developing type 2 diabetes/IGT for a short- and 
long-duration sleeper. Because some individuals in this family study are biologically related, we 
adjusted for clustering in the analyses to avoid underestimation of SD using the generalized 
estimating equations (GEE) statistical method. This procedure allowed us to model sleep duration 
and covariates as repeated measures at two time points (baseline and 6 years later). Data are 
given as means ± SD unless otherwise noted. Statistical significance was set at a p value <0.05. 
All statistical analyses were performed using the JMP version 5.1.2 program (SAS Institute, 
Cary, NC, USA).   
 
RESULTS 
 Regarding baseline characteristics of men and women in the study, men had higher body 
weight, waist circumference and waist-to-hip ratios than women, whereas women had greater 
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percentage of body fat than men. However, age, BMI, body fat mass and total sleep duration 
were not significantly different between sexes. Table 1 presents baseline characteristics of 
subjects by sleep duration category. Short-duration sleepers presented higher body weight, BMI, 
percent body fat, abdominal circumference, fasting insulin level, HOMA-IR index and GABF as 
compared to average-duration sleepers. However, we were not able to detect any significant 
difference between the three sleeper groups for demographic characteristics, fasting glucose 
level, total glucose and insulin AUC, resting metabolic rate, and total caloric intake. Short-
duration sleepers reported more vigorous physical activity participation than did average-duration 
sleepers.     
Table 2 shows the factors that affect the risk of new diabetes or IGT during the 6-year 
follow-up period (unadjusted analysis). Age, short and long sleeping time, high adiposity indices, 
and elevated resting metabolic rate were associated with new cases of type 2 diabetes/IGT. 
Furthermore, glucose and insulin homeostasis indicators, annual family income, and shift-
working history were predictors of type 2 diabetes/IGT over the follow-up period. In multiple 
regression models, only age, obesity, sleep duration and glucose/insulin homeostasis indicators 
were significantly and independently associated with new cases of type 2 diabetes/IGT. On the 
other hand, shift-working history, participation in vigorous physical activity, employment status, 
smoking habits, and coffee intake were independent predictors of sleep duration (data not 
tabulated).   
Using adults with 7-8 h of sleep as the reference group, the adjusted RR for the 
development of type 2 diabetes/IGT was 2.78 (1.61-4.12) for the ≤6 h of sleep and 2.54 (1.42-
3.53) for the ≥9 h of sleep groups (Table 3). After adjusting for waist circumference, those who 
slept 6 or fewer hours per day (RR = 2.42, 95% CI 1.49-3.33) and those who slept 9 or more 
hours (RR = 2.31, 95% CI 1.41-3.15) continued to be significantly more likely to have incident 
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diabetes/IGT. Consistent with our hypothesis that obesity would act as a partial mediator of the 
relationship between sleep duration and the incidence of diabetes/IGT, the addition of waist 
circumference, BMI or percent body fat further attenuated the results.        
 
DISCUSSION 
The primary result of this study is that both short and long sleeping times are associated 
with a higher risk of developing type 2 diabetes/IGT. This finding is consistent with the majority 
of other studies investigating the association of sleep time with type 2 diabetes [10,11,27]. 
Furthermore, our results concur with a growing body of epidemiological evidence showing a U-
shaped relationship between sleep duration and body weight [28,29], type 2 diabetes [11,27], 
coronary heart disease [30], and all-cause mortality [31]. Thus, a body of data suggests that there 
may be an “optimal sleeping time” of about 7-8 h per night in adults for the prevention of 
common diseases and premature death.  
We are only beginning to recognize the hormonal and metabolic implications of variation 
in sleep duration. Physiological data suggest that short-term partial sleep restriction leads to 
striking alterations in metabolic and endocrine functions including decreased carbohydrate 
tolerance, insulin resistance, increased sympathetic tone, elevated cortisol concentrations, 
elevated levels of pro-inflammatory cytokines, and decreased leptin and increased ghrelin levels 
[7,28,32]. These findings suggest that long-term sleep curtailment may predispose individuals to 
abnormal metabolic regulation, including overt clinical diabetes. On the other hand, the 
mechanisms mediating the association of long sleep time with type 2 diabetes/IGT are more 
speculative. One plausible explanation is the sleep inducing and metabolic effects of pro-
inflammatory cytokines which are elevated in the obese and in those with insulin resistance 
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[33,34]. Long sleep duration could also be reflective of sleep disorders such as sleep-disordered 
breathing which is associated with obesity, insulin resistance, and diabetes [35]. Seven days of 
extending the time spent in bed to 12 h per night was not associated with evidence of glucose 
intolerance [7]. Nurses’ Health Study participants who reported sleeping 9 h or more per night 
reported 15% less physical activity per week than those sleeping 7-8 h per night [9]. This could 
result in a higher level of sedentariness which could over time favor impaired glucose regulation. 
However, the statistical adjustment for physical activity level in the present study has not 
provided support for this notion. One cannot exclude that some unmeasured variables may have 
confounded this association. In addition, we need to consider the possibility that self-reported 
long-duration sleepers are spending a lot of time in bed but not getting a lot of sleep, i.e. they 
might have poor sleep quality possibly due to sleep disorders or other health issues. Accordingly, 
the effects of prolonged sleep on biological mechanisms remain to be understood. 
In the present study, adiposity was a risk factor for the development of type 2 
diabetes/IGT in the multivariate adjusted model. Since obesity is a well-known risk factor for 
insulin resistance and type 2 diabetes, we hypothesized that the association between sleep 
duration and type 2 diabetes/IGT could be due to a confounding effect of adiposity or that 
sleeping time might mediate its effects on diabetes through weight gain. Consistent with our 
hypothesis, we observed that adjustment for adiposity attenuated the association of sleep time 
with type 2 diabetes/IGT, even though the association continued to be statistically significant. 
This finding is concordant with that of epidemiologic studies of sleep duration and diabetes risk 
[9-11,27]. Globally, these results suggest that the effects of sleep on subsequent onset of overt 
diagnosis of type 2 diabetes are not well understood. Additional studies using objective measures 
of sleep are required to determine if sleep curtailment and/or extension is truly part of the causal 
mechanisms leading to the development of diabetes.  
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Another aspect that deserves attention in this study is the fact that we did not find a gender 
difference in the risk of future diabetes by sleep duration. Mallon et al. [10] showed that the RR 
for the development of diabetes was significantly higher in men with short sleep duration (RR of 
2.8) or difficulties maintaining sleep (RR of 4.8), after adjustment for age and other relevant risk 
factors, as compared to men reporting normal sleep patterns. Short or long sleep duration or sleep 
complaints did not, however, influence the risk of new diabetes in women in the same 
population-based study. On the other hand, the cross-sectional multicenter study from 
Tuomilehto et al. [36] reported a stronger association in women than in men, both for long and 
for short sleep duration, after controlling for obesity and other risk factors. The Nurses Health 
Study demonstrated an association between the amount of sleep and developing symptomatic 
diabetes in women [9]. Since the majority of studies have been conducted only in men, it is 
difficult to determine if there is indeed a gender effect.     
Another issue pertains to glucose concentrations at the end of the OGTT, as we recently 
published results showing that short-duration sleepers presented lower glycemia at the end of an 
oral glucose challenge [15]. According to the glucostatic theory of appetite control [16], low 
glycemia is sufficient to trigger episodes of hunger and food intake. Thus, one could speculate 
that chronic lack of sleep stimulates appetite, promoting weight gain and impairing glycemic 
regulation, with a subsequently increased risk of IGT and eventually type 2 diabetes. Here again, 
the GABF was significantly higher in short-duration sleepers compared with average-duration 
sleepers and was a significant predictor of type 2 diabetes/IGT over the follow-up period. The 
addition of GABF in the multivariate logistic regression model (not shown) attenuated the RR for 
the incidence of type 2 diabetes/IGT in short-duration sleepers. Thus, this observation supports 
the hypothesis that GABF would act as a partial mediator of the relationship between sleep 
duration and type 2 diabetes/IGT.      
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Strengths of this study include its longitudinal design and use of objective measures of 
adiposity and glycemic status. Furthermore, data were obtained from both men and women and 
we used an approach that should serve to minimize confounding with repeated measures of sleep 
duration and covariates. However, the small sample size limits statistical power and 
generalizability of the results. Another limitation of the study was the use of self-reported sleep 
durations, as opposed to measured sleep durations. Although good agreement has been found in 
previous studies between self-reported sleep durations and those obtained through actigraphic 
monitoring [37,38], the validity of the single question method has not been fully determined. In 
addition, weekday and weekend sleep duration may differ significantly, with some individuals 
having a tendency to recapture sleep debt on the weekends. Finally, the possibility of a 
confounding effect in the relation of sleep time to type 2 diabetes/IGT from unmeasured variables 
such as sleep-disordered breathing, insomnia or depression, cannot be excluded.   
In conclusion, data from this prospective cohort of adults suggest that sleep duration is a 
risk factor for the development of type 2 diabetes/IGT in both sexes. Both short and long sleep 
durations were associated with an increased incidence of type 2 diabetes/IGT, resulting in a U-
shaped distribution of risk. This study lends empirical support to other published reports that 
indicate that the practice of good sleep hygiene is crucial and should be included with other 
behaviors to achieve good health.            
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Table 1.  Baseline characteristics of subjects according to sleep duration group.1 
——————————————————————————————————————— 
                 ≤6 hours              7-8 hours              ≥9 hours                
                  (n = 43)              (n = 197)               (n = 36) 
Variable                
——————————————————————————————————————— 
Age (years)    39.9 ± 14.9  38.9 ± 14.8  37.3 ± 18.2 
Sex 
   Male     21 (49)  85 (43)  11 (31) 
   Female    22 (51)  112 (57)  25 (69) 
Body weight (kg)   76.9 ± 14.7*  69.3 ± 14.9  72.4 ± 23.3  
BMI (kg/m2)               27.8 ± 5.5*  25.0 ± 4.7  26.1 ± 6.4         
Body fat mass (kg)              22.6 ± 10.8*  17.8 ± 9.3  19.6 ± 11.1         
Body fat (%)               28.5 ± 9.1*  25.2 ± 9.3  26.6 ± 9.3         
Waist circumference (cm)   90.1 ± 15.0*  82.5 ± 14.0  83.8 ± 17.0 
RMR (kcal/24 h)                              1531 ± 295            1474 ± 253            1470 ± 311 
Fasting glucose level (mmol/L)  5.10 ± 0.57  5.04 ± 0.50  4.89 ± 0.49 
Fasting insulin level (pmol/L)  85.1 ± 71.1*  58.1 ± 45.7  79.2 ± 67.2 
Total glucose AUC (mmol/L×min)   1151 ± 208            1135 ± 247            1202 ± 234 
Total insulin AUC (pmol/L×min)      79862 ± 52620 68762 ± 61101 87623 ± 83271 
HOMA-IR index    3.18 ± 2.45*  2.22 ± 1.92  2.94 ± 2.66 
GABF (mmol/L×min)    52.6 ± 16.4*  29.7 ± 18.7  39.1 ± 19.8 
Smoking habits 
   Non or ex-smoker    36 (83)  172 (87)  32 (89) 
   Light smoker2    2 (5)   12 (6)   3 (8) 
   Heavy smoker3    5 (12)   13 (7)   1 (3) 
Employment status 
   Student     7 (16)   43 (22)  7 (19) 
   Paid employment    25 (58)  116 (59)  18 (50) 
   Looking for work    2 (5)   5 (2)   2 (6) 
   Home duties    4 (9)   21 (11)  4 (11) 
   Retired     3 (7)   10 (5)   4 (11) 
   Disabled     2 (5)   2 (1)   1 (3) 
Highest educational level 
   High school     21 (49)  83 (42)  18 (50) 
   Pre-university level4   14 (32)  72 (37)  12 (33) 
   University     8 (19)   42 (21)  6 (17) 
Total annual family income5   
   $70,000 or more    14 (32)  76 (38)  13 (36) 
   $50,000-$69,000    13 (30)  55 (28)  9 (25) 
   $30,000-$49,000    12 (28)  60 (30)  12 (33) 
   $10,000-$29,000    2 (5)   2 (1)   1 (3) 
   <$10,000     2 (5)   4 (2)   1 (3) 
Menopausal status 
   In menopause    6 (14)   22 (11)  4 (11) 
   Not in menopause    37 (86)  175 (89)  32 (89) 
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Shift-working history 
   None     35 (81)  166 (84)  28 (78) 
   <5 years     5 (12)   22 (11)    5 (14) 
   ≥5 years     3 (7)   9 (5)   3 (8) 
Alcohol intake (g/day)   7.58 ± 15.2  6.97 ± 13.3  7.55 ± 17.8 
Coffee intake (cups/day)   3.00 ± 2.35  2.61 ± 2.11  2.51 ± 2.53 
Energy intake (kcal/day)             2505 ± 676            2314 ± 713            2253 ± 570 
Vigorous PA6 (min/day)             14.7 ± 28.9  6.4 ± 9.8*            7.9 ± 11.3        
——————————————————————————————————————— 
BMI = body mass index; RMR = resting metabolic rate; AUC = area under the curve; HOMA-IR 
= homeostasis model assessment of insulin resistance; GABF = glucose area below fasting glucose 
concentration; PA = physical activity. 
*Significantly different from the 7-8 hours sleeping group (p<0.05). 
1Unless otherwise stated, values represent number, with percentage in parentheses. 
2 ≤10 cigarettes per day. 
3 >10 cigarettes per day. 
4In Quebec, it is a level of education of 2 years between high school (grade 11) and university 
(grade 13) termed CEGEP (Collège d’Enseignement Général et Professionnel). 
5Canadian dollars (CAD). 
6Mean time spent in vigorous physical activity participation estimated as the number of periods 
graded 8 and 9 over the 3 days.  
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Table 2.  Predictors of type 2 diabetes/IGT over the follow-up period.  
——————————————————————————————————————— 
                  
                                 Type 2 diabetes/IGT  
                        ————————————————————   
Predicting variable                             β                     r                       p 
——————————————————————————————————————— 
Age (years)      0.01  0.29  <0.01  
Gender               –0.06  0.14    0.13 
Study phase               0.01  0.04    0.54 
Length of follow-up     0.02  0.04    0.56 
Sleep duration (h)              –0.08  0.17    0.04 
Body weight (kg)     0.01  0.36   <0.01   
BMI (kg/m2)      0.03  0.33  <0.01     
Body fat mass (kg)     0.02  0.41  <0.01                
Body fat (%)      0.01  0.26  <0.01            
Waist circumference (cm)    0.02  0.45  <0.01 
RMR (kcal/24 h)     0.01  0.33  <0.01              
Fasting glucose level (mmol/L)   0.98  0.62  <0.01 
Fasting insulin level (pmol/L)   21.7  0.21  <0.01 
Total glucose AUC (mmol/L×min)   0.01  0.53  <0.01 
Total insulin AUC (pmol/L×min)           <0.01  0.23  <0.01 
HOMA-IR index     0.09  0.38  <0.01 
GABF (mmol/L×min)     0.01  0.34  <0.01 
Smoking habits     0.01  0.01    0.88  
Employment status              –0.02  0.05    0.44  
Educational level              –0.02  0.03    0.63  
Total annual family income             –0.09  0.36  <0.01   
Menopausal status     0.20  0.14    0.13     
Shift-working history     0.02  0.17    0.04 
Alcohol intake (g/day)    0.01  0.06    0.41  
Coffee intake (cups/day)    0.01  0.04    0.55  
Energy intake (kcal/day)            <0.01  0.12    0.10            
Vigorous PA (min/day)            <0.01  0.01    0.74               
——————————————————————————————————————— 
BMI = body mass index; RMR = resting metabolic rate; AUC = area under the curve; HOMA-IR 
= homeostasis model assessment of insulin resistance; GABF = glucose area below fasting glucose 
concentration; PA = physical activity. 
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Table 3.  Relative risk for the incidence of type 2 diabetes or IGT by sleep duration group.  
——————————————————————————————————————— 
     Type 2 diabetes/IGT     Multivariate        Multivariate 
        n     %        adjusteda                      adjustedb                                        
——————————————————————————————————————— 
Sleeping time 
   ≤6 h        9   20.9    2.78 (1.61-4.12)     2.42 (1.49-3.33) 
   7-8 h      14     7.1    1.00       1.00               
   ≥9 h             7   19.4    2.54 (1.42-3.53)     2.31 (1.41-3.15)  
——————————————————————————————————————— 
Data are RR (95% CI). 
aModel adjusted for age, smoking habits, employment status, annual household income, shift-
working history, resting metabolic rate, coffee intake, and participation in vigorous physical 
activity. These variables were chosen because they were either associated with sleep duration 
and/or type 2 diabetes/IGT over the follow-up.   
bModel adjusted for the above-mentioned covariates plus waist circumference. Results were not 
materially different after controlling for BMI or percent body fat instead of waist circumference. 
Note: Covariates (including obesity covariates) were modeled as repeated measures at two time 
points (baseline and 6 years later), thus taking into account the evolution of both measures over 
time.   
  
